IHS Chemical Week

CHEM IDEAS

An Interpretation of U.S. FDA Guidance for Pharma Manufacture

8:45 AM MDT | October 19, 2009 | By GIRISH MALHOTRA

About five years ago FDA issued its “PAT [Process Analytical Technology] Guidance for Industry”. FDA’s intent by issuing the guidelines is to encourage the pharmaceutical industry to improve and innovate its manufacturing practices so that they produce quality product the first time and all the time. Manufacturing innovation will be the lifeline for the pharmaceuticals sector as its business model changes.

 

Regulatory bodies want the companies to move away from achieving quality through the current practice of “after the fact repeated analysis”. Achieving product quality “the first time” and all the time is the goal. This is not a difficult expectation.

 

The guideline is suggesting to the industry how and what needs to be done and the methodology for improving the processes. However, innovation has to come from within the industry rather than be thrust upon it. The guidance is full of legalese and can be interpreted in many different ways. As written, it eludes more to drug formulation than to Active Pharmaceutical Ingredient (API) manufacture. However, the rules of the game for API and drug formulation are same; quality is the ultimate goal.

 

If we clear the forest and the legal jargon, FDA is saying “understand how the chemicals react, interact and behave with each other and have a process that-if operated at the desired process conditions-should deliver quality product the “first time” and all the time.” This implies the use of basic tenants of chemical engineering, chemistry curriculum and process development. Anything short will not deliver first time quality product.

 

In product and process development, we need to understand the chemicals, their interaction, establish specifications and use different analytical technologies to ensure that the developed process will deliver the expected product. If one is expecting that the process analytical technologies will fix a bad process, then that would be a gross error and expectation. Analytical technologies tell us the result rather than the path to the result. 

 

Good manufacturing practices and continuous improvement are a must for every manufacturer. PAT guidance suggests that the pharmaceutical industry should have discussions and approvals from FDA on their existing process improvement plans. This is adding costs. The benefits of process improvement can be quantified but since the re-approval costs are not known, my conjecture is that the industry would not opt for any process improvement for their existing products as the costs could exceed the benefits. Estimated savings due to process innovations for the pharmaceutical companies are in the $100-200 billion dollars range. I hope this is good incentive to innovate.

 

Pharmaceutical companies are unable to apply good chemistry and engineering principles to have an efficient process that produces quality product, due to market pressures as well as the effects of regulatory directives and guidelines. The current state of pharmaceutical manufacture is a manifestation of our methods. Pharmaceutical companies have to take the lead if we are to expect change. Innovation can happen for the products that will become generic in the coming years and for the new molecules that will be commercialized.

 

Development of innovative processes has to start during the process conceptualization and development. Even then it would require effort, as old methods and thinking would have to be discarded-which is not easy. The regulatory bodies will have to be flexible and encourage innovation. PAT guidelines and other guidelines are encouraging innovation but have too many constraints. I strongly believe that innovation can reduce regulation.

 













 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2012 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa